Patent ID: 8629107

Claim:
A method for determining the presence of uterine tumor cells in a patient being diagnosed for uterine cancer, comprising: a) obtaining a test sample from the patient; b) performing an assay to detect a level of nucleic acid expression of Microfibril-associated glycoprotein-2 (MAGP-2) in the test sample from the patient; and c) comparing the level of nucleic acid expression of MAGP-2 in the test sample to MAGP-2 nucleic acid expression of a control sample determined by performing an assay to detect MAGP-2 level of nucleic acid expression in the control sample, wherein detection of a statistically significant increase in the MAGP-2 nucleic acid expression in the test sample, as compared to the MAGP-2 nucleic acid expression in the control sample, is an indicator of the presence of tumor cells in the test sample as compared to cells in the control sample, and wherein the control sample level is established from a negative control sample that is established as non-tumorigenic.